Resource-sparing curative-intent hypofractionated-accelerated radiotherapy in head and neck cancer: More relevant than ever before in the COVID era
Authors:
- Tejpal GuptaTGTejpal Gupta
- Sarbani Ghosh-LaskarSGSarbani Ghosh-Laskar
- Jai Prakash AgarwalJAJai Prakash Agarwal
- 1 December 2020
- journal article
- research article
- Published by Elsevier in Oral Oncology
- Vol. 111, 105045
Abstract
No abstract availableKeywords
Funding Information
- International Atomic Energy Agency
- Tata Memorial Centre
This publication has 31 references indexed in Scilit:
- Synchronous Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck using Capecitabine: a Single-centre, Open-label, Single-group Phase II StudyClinical Oncology, 2011
- Hypofractionated Accelerated Radiotherapy with Concurrent Carboplatin for Locally Advanced Squamous Cell Carcinoma of the Head and NeckClinical Oncology, 2011
- Can Synchronous Chemotherapy be Added to Accelerated Hypofractionated Radiotherapy in Patients with Base of Tongue Cancer?Clinical Oncology, 2010
- Radiobiological Modelling of the Therapeutic Ratio for the Addition of Synchronous Chemotherapy to Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and NeckClinical Oncology, 2010
- Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trialThe Lancet Oncology, 2010
- Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patientsRadiotherapy and Oncology, 2009
- Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysisThe Lancet, 2006
- The potential for mathematical modelling in the assessment of the radiation dose equivalent of cytotoxic chemotherapy given concomitantly with radiotherapyBritish Journal of Radiology, 2005
- Altered fractionation and combined radio-chemotherapy approachesEuropean Journal of Cancer, 2003
- From chemoprevention and organ preservation programmes to postoperative managementEuropean Journal of Cancer, 2002